AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$APGE

Shah Nimish P sold (to issuer) $236.4M of APGE (indirect holdings)

Shah Nimish P sold (to issuer) 1,750,000 indirectly-held shares of Apogee Therapeutics, Inc. (APGE) at $135.11 ($236.44M total) on 2026-09-03.

Original reporting
SEC EDGAR · Shah Nimish P
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$APGE
Bearish
high confidence
Mentioned
$APGE
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$APGEBearishMed
01

Why it matters

The director's complete exit may influence market perception of APGE.

02

Market read

Large insider sell could trigger short‑term volatility in APGE.

03

What to watch

Sale executed via a 10b5-1 plan could be pre‑scheduled, reducing informational value.

Relevance 8/10Novelty 8/10Timing: today

Background

Form 4 filing discloses insider transactions to the SEC.

Company-level read

Ticker impact

$APGEBearishHigh confidence
Context

Director Shah Nimish P sold 1.75M shares for $236.4M, reducing holdings to zero.

Expected impact

potential short-term price decline

Evidence & confidence

Sale size exceeds $200M and eliminates insider stake, a material negative catalyst.

Market effects

Sector

May raise concerns for biotech sector insiders' confidence.

Regional

Limited to US biotech investors.

Global

Low global impact, primarily affects APGE shareholders.

Counterpoint

What could challenge this read

Insider may be diversifying portfolio, not necessarily a negative signal.

Key entities

  • Company
    Apogee Therapeutics, Inc.

    Biotech firm listed on NASDAQ.

  • Insider
    Shah Nimish P

    Director of Apogee Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

APGE insider trading history →

Related articles

SEP 9
$ABBVHighAI 9/10

Is AbbVie (ABBV)’s $10.9 Billion Apogee Therapeutics (APGE) Deal the Next Catalyst for Growth?

AbbVie (ABBV) completed its $10.9B acquisition of Apogee Therapeutics (APGE) at $135.11 per share. AbbVie also reported positive Phase 3 trial results for etentamig. Q2 2026 revenue for AbbVie rose 10.2% to $16.99B, with adjusted EPS up 22.9% to $3.65. Apogee reported a net loss of $85.9M in Q2 2026. Hedge funds increased stakes in both companies ahead of the deal.

insidermonkey.com3 min
SEP 3
$ABBVHighAI 9/10

AbbVie Completes $10.9 Bln Acquisition Of Apogee Therapeutics

AbbVie (ABBV) completed its $10.9 billion acquisition of Apogee Therapeutics (APGE), paying $135.11 per share. The deal strengthens AbbVie's immunology pipeline, including Apogee's lead asset, zumilokibart, for atopic dermatitis. AbbVie expects the acquisition to be dilutive to earnings until 2032. AbbVie reaffirmed its 2026 EPS guidance of $13.87-$14.07, including a $0.14 per-share dilutive impact. ABBV closed at $261.72, up 0.67%.

rttnews.com2 min
SEP 2
$MMEDMed

Biotech Stocks At 52-Week Highs - MMED +10%, PLSE, SOLV, RPRX, APGE

Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.

rttnews.com2 min